I agree 100% with this statement from Ipix. It is clear and obvious to any person who knows Ipix affairs. "Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully." Ipix is a small biotech company in clinical stage only. It is normal. All small biotech companies like Ipix need a much more large pharmaceutical company partner and a lot in partner money to "advance drug candidates meaningfully." You know this. This statement has no relations with natural value of drug candidate Brilacidin. But sure Ipix today does not have the big money for a new clinical trial. They need a partner for this.
So why does Ipix not have this big partner? Ipix-model R**n was alive 18 years before they could make a deal with a first pharmaceutical partner. Maybe you remember it was 20 years for them to have a first drug approved by USA FDA? For me there are only two reasons a small biotech company and shareholders maybe wait a long time for a good partner deal and money to "advance meaningfully" a drug property. My opinions are simple. 1* The science is not good and the partner offer is super small or there is no interest. Maybe there is not enough research or the candidate shows only small possibility to work or be approved. Maybe the market size and possible profit are too small for any partner. 2* The science is good but the offer is not enough. Good science and big potential market and profit deserves a good offer. Shareholders deserve a good offer also. They also own part of the science. Super good science deserves a super good offer.
I own a lot of Ipix and I am confident about the science and research and clinical trial success and safety history with Brilacidin. I am confident the USA FDA is comfortable with Brilacidin. They give it two Fast Tracks and one QIDP. I am confident about the Brilacidin markets and possible profit. Maybe you remember Ipix has already made a deal with a partner that can be worth USD$24 million plus 6% royalty. This was for a only a small possible market. And now there are so many in the list! Independent research finds a new Brilacidin market almost every year as they test all the drug can do. Maybe you saw some of this: https://www.google.com/search?client=firefox-b-1-d&q=brilacidin+google+scholar
Now what is the next paragraph after the Ipix drug advance statement? I will help: "In the ordinary course of business, we engage in a continual review of opportunities to license our drug compound(s)/ indications and enter into partnering, joint development or similar arrangements with other companies. We may generally at any time have such opportunities in various stages of active review, including, for example, entry into indications of interest and term sheets and participation in preliminary discussions and negotiations. Any such transaction could be material to us."
I wonder what is the stage of "active review" for a Merck or the Swiss company offer for "partnering, joint development or similar arrangements" for one of the many Brilacidin markets? There is a lot of money that can be made from Brilacidin for a big partner. Here is one example. There are many others. https://www.biorxiv.org/content/10.1101/2022.09.28.509882v1
News 
Market Data 
Discover 
